Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top